HEALTHCARE
CLINICAL TRIAL SUPPLIES MARKET Global Forecast to 2020
REPORT CODE PH 3772
CLINICAL TRIAL SUPPLIES MARKET - GLOBAL FORECAST TO 2020 By Products & Services (Logistics & Distribution, Manufacturing, Packaging&Labeling), Phases (Phase I, Phase II, Phase III) & Therapeutic Areas (CNS & Mental Disorder, Cardiovascular, Oncology)
REPORT OVERVIEW 1.1
OBJECTIVES OF THE STUDY •
To define, describe, and forecast the global clinical trial supplies market on the basis of products and services, therapeutic areas, phases, and regions
•
To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
•
To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
•
To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders
•
To forecast the size of the global clinical trial supplies market with respect to four main regions (along with countries), namely, North America, Europe, Asia-Pacific, and the Rest of the World
•
To strategically profile the key players in the global clinical trial supplies market and to comprehensively analyze their core competencies and market shares
•
To track and analyze competitive developments such as agreements, partnerships, and alliances; acquisitions; new product developments; expansions; and research and development activities in the global clinical trial supplies market
sales@marketsandmarkets.com
www.marketsandmarkets.com
1
INTRODUCTION
1.2 •
Clinical trial supplies include products used in the processes of manufacturing, packaging and labelling, and logistics and distribution of drug. Clinical trial supplies are widely used in all therapeutic areas including oncology, blood disorders, dermatology, CNS and mental disorders, infectious diseases, and cardiovascular diseases to conduct clinical trials related to particular therapy area.
1.3 •
MARKET DEFINITION
MARKET SCOPE The clinical trial supplies market report includes manufacturing, packaging and labeling, and logistics and distribution services for clinical trial supplies. The clinical trial supplies market in the report includes only clinical trial supplies services which are outsourced by sponsors (pharmaceutical companies) to CROs and logistic companies.
1.3.1 MARKET SEGMENTATION •
This research report categorizes the clinical trial supplies market into the following segments: • FIGURE 1
CLINICAL TRIAL SUPPLIES MARKET
•
•
•
•
•
•
•
•
•
• • • • •
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
2
INTRODUCTION
• GLOBAL CLINICAL TRIAL SUPPLIES MARKET, BY REGION •
•
•
•
North America •
U.S.
•
Canada
Europe •
Germany
•
France
•
U.K.
•
Spain
•
Rest of Europe
Asia-Pacific •
China
•
Japan
•
India
•
Rest of Asia- Pacific
Rest of the World
1.3.2 YEARS CONSIDERED FOR THE STUDY •
sales@marketsandmarkets.com
www.marketsandmarkets.com
3
INTRODUCTION
1.4 CURRENCY •
For companies reporting their revenue in USD, the revenues were picked from their annual reports
•
For companies reporting their revenues in other currencies, average annual currency conversion rate was used for the particular year to convert the value to USD
1.5 LIMITATIONS •
The report does not cover country-level quantitative information (value market) for the RoW market due to the availability of limited information from primary and secondary sources. However, the report provides country-level qualitative information
•
The volume market is not included in the report due to limited information available from secondary as well as primary sources
1.6 STAKEHOLDERS •
Biopharmaceutical drug manufacturers
•
Private equity companies and venture capital firms
•
Healthcare service providers (hospitals and independent physicians)
•
Health insurance payers
•
Research and consulting service firms
•
Contract manufacturing organizations (CMOs)
•
Pharmaceutical and medical associations
sales@marketsandmarkets.com
www.marketsandmarkets.com
4
RESEARCH METHODOLOGY
2
RESEARCH METHODOLOGY •
This research study involved the usage of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies. Secondary research was mainly used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the global clinical trial supplies market. It was also used to obtain key information about the major players, market classification and segmentation according to the industry trends, regional markets, and developments related to the market and technology perspectives.
•
Primary sources involved in this research study are industry experts from core and related industries; preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and laboratory technicians; and organizations related to all segments of this industry‘s value chain. In-depth interviews were conducted from various primary respondents which included key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify critical qualitative and quantitative information as well as to assess future growth prospects. The following figure illustrates the market research methodology employed for the purpose of this study. • FIGURE 2
RESEARCH DESIGN
•
•
•
• • •
•
•
•
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
5
RESEARCH METHODOLOGY
•
In the secondary research process, various secondary sources were referred to for identifying and collecting information useful for this study. These secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases.
•
Secondary research was mainly used to obtain key information about the industry‘s supply chain, leading and emerging players, market classification and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments from both market and technology-oriented perspectives.
•
In the primary research process, various primary sources from both the supply- and demand-side were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supplyside include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the clinical trial supplies market. Primary sources from the demand side includes clinical trial supplies product manufacturers, R&D professionals, and technicians.
•
After the complete market engineering (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and to verify and validate the critical numbers arrived at. Primary research was also conducted to identify and study the segmentation types; industry trends; key players; competitive landscape for clinical trial supplies market and end products supplied by different market players; and key market dynamics such as drivers, restraints, opportunities, and key player strategies.
•
In the complete market engineering process, both top-down and bottom-up approaches were extensively used along with several data triangulation methods to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
2.1 •
MARKET SIZE ESTIMATION Both top-down and bottom-up approaches were used to estimate and validate the size of the global market and estimate the size of various other dependent submarkets in the overall clinical trial supplies market. The key players in this market were identified through secondary research and their market shares in the respective geographies were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
6
RESEARCH METHODOLOGY
•
The following figure shows an illustrative representation of the overall market size estimation process employed for the purpose of this study. • FIGURE 3
TOP-DOWN APPROACH
• FIGURE 4
BOTTOM-UP APPROACH
•
•
•
The bottom-up procedure was adopted to arrive at the overall size of the global clinical trial supplies market from the revenue of key players (companies) and their shares in the market, and annual sales of clinical trial supplies based on the type of product.
•
Calculations based on the revenue of key companies and sales of clinical trial supplies of those companies identified in the market led to the overall market size. This overall market size was used in the top-down procedure to estimate the size of other individual markets mentioned in the market segmentation through percentage splits from secondary and primary research.
sales@marketsandmarkets.com
www.marketsandmarkets.com
7
RESEARCH METHODOLOGY
•
For the calculation of each type of specific market segment, the most appropriate immediate parent market size was used for implementing the top-down procedure. The bottom-up procedure was also implemented to validate the market segment revenues obtained from data extracted from secondary research.
•
Market shares were then estimated for each company to verify the revenue shares used earlier in the bottom-up procedure. With the data triangulation procedure and validation of data through primaries, the exact values of the overall parent market size and each individual market size were determined and confirmed in this study. The data triangulation procedure implemented for this study is explained in the next section. • FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, & REGION
• 9%
25%
35%
40% Tier-1
2.2 •
Tier-2
35%
40%
25% Tier-3
C-level
43%
29%
Director-level
19% Others
North America
Europe
Asia
RoW
•
Note: Tier of the companies is defined on the basis of their total revenue, as of 2014; Tier 1 = > USD 7 Billion, Tier 2 = USD 500 Million to USD 7 Billion, and Tier 3 = < USD 500 Million
•
Others include sales managers, marketing managers, and product managers.
MARKET BREAKDOWN AND DATA TRIANGULATION After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. In order to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches. •
sales@marketsandmarkets.com
www.marketsandmarkets.com
8
RESEARCH METHODOLOGY
• FIGURE 6
DATA TRIANGULATION METHODOLOGY
•
• • •
• • •
2.3 •
• •
MARKET SHARE ESTIMATION The market shares for the key players have been calculated on the basis of secondary data available through paid and unpaid sources and by analyzing the product portfolios of the top companies. This data was further validated through expert interviews.
sales@marketsandmarkets.com
www.marketsandmarkets.com
9
RESEARCH METHODOLOGY
2.3.1 KEY DATA FROM SECONDARY SOURCES • • • • • • •
• • • • • • • •
2.3.2 KEY DATA FROM PRIMARY SOURCES •
sales@marketsandmarkets.com
www.marketsandmarkets.com
10
RESEARCH METHODOLOGY
2.3.3 KEY INDUSTRY INSIGHTS •
2.4 • •
ASSUMPTIONS FOR THE STUDY The following assumptions were taken into consideration to complete the overall market engineering of the clinical trial supplies market: PARAMETER
sales@marketsandmarkets.com
ASSUMPTION
www.marketsandmarkets.com
11
TABLE OF CONTENTS
1 INTRODUCTION.........................................................................................................................14 •
1.1
OBJECTIVES OF THE STUDY...........................................................................................................................................14
•
1.2
MARKET DEFINITION.......................................................................................................................................................14
•
1.3
MARKET SCOPE...............................................................................................................................................................14
•
1.3.1
MARKET SEGMENTATION..............................................................................................................................15
•
1.3.2
YEARS CONSIDERED FOR THE STUDY.........................................................................................................16
•
1.4 CURRENCY......................................................................................................................................................................16
•
1.5 LIMITATIONS....................................................................................................................................................................16
•
1.6 STAKEHOLDERS...............................................................................................................................................................16
2
RESEARCH METHODOLOGY.....................................................................................................17 •
2.1
MARKET SIZE ESTIMATION.............................................................................................................................................18
•
2.2
MARKET BREAKDOWN AND DATA TRIANGULATION......................................................................................................21
•
2.3
MARKET SHARE ESTIMATION.........................................................................................................................................22
•
2.3.1
KEY DATA FROM SECONDARY SOURCES.......................................................................................................................22
•
•
2.3.2
KEY DATA FROM PRIMARY SOURCES..........................................................................................................23
•
2.3.3
KEY INDUSTRY INSIGHTS.............................................................................................................................23
2.4
ASSUMPTIONS FOR THE STUDY....................................................................................................................................24
3
EXECUTIVE SUMMARY..............................................................................................................25
4
PREMIUM INSIGHTS.................................................................................................................30 •
4.1
CLINICAL TRIAL SUPPLIES MARKET..............................................................................................................................30
•
4.2
CLINICAL TRIAL SUPPLIES MARKET SHARE, SERVICES VS. REGIONS.........................................................................31
•
4.3
GEOGRAPHIC ANALYSIS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE..................................................................32
•
4.4
GEOGRAPHIC ANALYSIS: CLINICAL TRIAL SUPPLIES MARKET, BY PRODUCT.............................................................33
•
4.5
LIFECYCLE ANALYSIS, BY REGION.................................................................................................................................34
sales@marketsandmarkets.com
www.marketsandmarkets.com
12
TABLE OF CONTENTS
5
MARKET OVERVIEW..................................................................................................................35 •
5.1 INTRODUCTION...............................................................................................................................................................36
•
5.2
•
CLINICAL TRIAL SUPPLIES: MARKET SEGMENTATION..................................................................................................36
•
5.2.1
BY PRODUCTS AND SERVICES.....................................................................................................................36
•
5.2.2
BY PHASE......................................................................................................................................................36
•
5.2.3
BY THERAPEUTIC AREA................................................................................................................................37
•
5.2.4
BY REGION.....................................................................................................................................................37
5.3 •
MARKET DYNAMICS........................................................................................................................................................38 5.3.1
•
5.3.1.1
GLOBALIZATION OF CLINICAL TRIAL ACTIVITIES...................................................................38
•
5.3.1.2
INCREASING R&D INVESTMENTS AND GOVERNMENT SUPPORT.........................................38
•
5.3.1.3
RISING INCIDENCES OF VARIOUS DISEASES..........................................................................39
•
5.3.1.4
INCREASING EXPANSION ACTIVITIES BY CROS.....................................................................39
•
5.3.2
• •
•
MARKET RESTRAINS.....................................................................................................................................40 5.3.2.1
LONGER APPROVAL TIMES FOR CLINICAL TRIALS................................................................40
5.3.3 OPPORTUNITIES............................................................................................................................................41
•
5.3.3.1
EMERGING MARKETS..............................................................................................................41
•
5.3.3.2
INCREASING NUMBER OF PATENT EXPIRATIONS AND DEVELOPMENT OF GENERIC DRUGS.. 41
5.4 •
6
MARKET DRIVERS.........................................................................................................................................38
INDUSTRY TRENDS.........................................................................................................................................................42 5.4.1
JUST–IN-TIME PACKAGING AND LABELING METHODS FOR CLINICAL TRIAL SUPPLIES..........................42
CLINICAL TRIAL SUPPLIES MARKET, BY PRODUCT AND SERVICE.........................................43 •
6.1 INTRODUCTION...............................................................................................................................................................44
•
6.2 MANUFACTURING...........................................................................................................................................................47
•
6.3
PACKAGING AND LABELING...........................................................................................................................................50
•
6.4
LOGISTICS AND DISTRIBUTION......................................................................................................................................52
sales@marketsandmarkets.com
www.marketsandmarkets.com
13
TABLE OF CONTENTS
7
CLINICAL TRIAL SUPPLIES MARKET, BY PHASE......................................................................55 •
7.1 INTRODUCTION...............................................................................................................................................................56
•
7.2
PHASE I............................................................................................................................................................................58
•
7.3
PHASE II...........................................................................................................................................................................59
•
7.4
PHASE III AND BIOEQUIVALENCE STUDIES....................................................................................................................60
8
CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA................................................62 •
8.1 INTRODUCTION...............................................................................................................................................................63
•
8.2 ONCOLOGY......................................................................................................................................................................65
•
8.3
CNS AND MENTAL DISORDERS......................................................................................................................................67
•
8.4
CARDIOVASCULAR DISEASES........................................................................................................................................68
•
8.5
INFECTIOUS DISEASES...................................................................................................................................................69
•
8.6
RESPIRATORY DISEASES.................................................................................................................................................70
•
8.7
BLOOD DISORDERS.........................................................................................................................................................71
•
8.8 DERMATOLOGY...............................................................................................................................................................72
•
8.9 OTHERS............................................................................................................................................................................73
9
CLINICAL TRIAL SUPPLIES MARKET, BY REGION....................................................................74 •
9.1 INTRODUCTION...............................................................................................................................................................75
•
9.2
NORTH AMERICA.............................................................................................................................................................76
•
9.2.1 U.S.................................................................................................................................................................79
•
9.2.2 CANADA.........................................................................................................................................................81
•
9.3 EUROPE............................................................................................................................................................................83 •
9.3.1 U.K.................................................................................................................................................................85
•
9.3.2 GERMANY......................................................................................................................................................86
•
9.3.3 FRANCE.........................................................................................................................................................87
•
9.3.4 SPAIN.............................................................................................................................................................88
•
9.3.5 ITALY..............................................................................................................................................................89
•
9.3.6
REST OF EUROPE (ROE)................................................................................................................................90
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
14
TABLE OF CONTENTS
•
•
10
9.4 ASIA-PACIFIC..................................................................................................................................................................91 •
9.4.1 CHINA............................................................................................................................................................94
•
9.4.2 INDIA..............................................................................................................................................................95
•
9.4.3 JAPAN............................................................................................................................................................96
•
9.4.4
9.5
REST OF ASIA-PACIFIC (ROAPAC)................................................................................................................97
REST OF THE WORLD (ROW)...........................................................................................................................................98
COMPETITIVE LANDSCAPE.....................................................................................................101
•
10.1 OVERVIEW......................................................................................................................................................................101
•
10.2
MARKET SHARE ANALYSIS...........................................................................................................................................102
•
10.3
COMPETITIVE SITUATIONS AND TRENDS.....................................................................................................................103
•
10.3.1 EXPANSION.................................................................................................................................................104
•
10.3.2
•
10.3.3 ACQUISITIONS.............................................................................................................................................105
•
10.3.4
•
10.3.5 OTHERS.......................................................................................................................................................107
11
AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND JOINT VENTURE.............................................104
NEW PRODUCT AND SERVICE LAUNCHES.................................................................................................106
COMPANY PROFILES...............................................................................................................108 •
(Overview, Financials, Products & Services, and Developments)*
•
11.1 INTRODUCTION.............................................................................................................................................................108
•
11.2
ALMAC GROUP LTD,......................................................................................................................................................109
•
11.3
CATALENT PHARMA SOLUTIONS, INC..........................................................................................................................112
•
11.4
PAREXEL INTERNATIONAL.............................................................................................................................................116
•
11.5
THERMO FISHER SCIENTIFIC, INC................................................................................................................................118
•
11.6
PCI SERVICES................................................................................................................................................................120
•
11.7
PATHEON, INC...............................................................................................................................................................122
•
11.8
SHARP PACKAGING SERVICES.....................................................................................................................................123
•
11.9 BIOCAIR.........................................................................................................................................................................125
•
11.10 MOVIANTO.....................................................................................................................................................................126
•
11.11 KLIFO A/S.......................................................................................................................................................................127
•
*Details on overview, financials, product & services, and developments might not be captured in case of unlisted companies.
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
15
TABLE OF CONTENTS
12 APPENDIX................................................................................................................................128 •
12.1
INSIGHTS OF INDUSTRY EXPERTS...............................................................................................................................128
•
12.2
DISCUSSION GUIDE......................................................................................................................................................129
•
12.3
INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE..............................................................................................132
•
12.4
AVAILABLE CUSTOMIZATIONS......................................................................................................................................132
•
12.5
RELATED REPORTS........................................................................................................................................................133
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
16
LIST OF TABLES
• TABLE 1
INCREASING EXPANSION ACTIVITIES BY CROS TO BOOST THE MARKET GROWTH FOR CLINICAL TRIAL SUPPLIES.......................................................................................................40
• TABLE 2
LONGER APPROVAL TIMES FOR CLINICAL TRIALS ARE RESTRAINING THE GROWTH OF THE MARKET................................................................................................................................40
• TABLE 3
GROWTH PROSPECTS IN EMERGING COUNTRIES TO FUEL THE MARKET GROWTH.....................................41
• TABLE 4
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCT AND SERVICE, 2013–2020 (USD MILLION)...............................................................................................................................44
• TABLE 5
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION).....................................45
• TABLE 6
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)...............................................................................................................................45
• TABLE 7
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)...................46
• TABLE 8
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)..........46
• TABLE 9
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR MANUFACTURING SERVICES, BY REGION, 2013–2020 (USD MILLION).........................................................................................................48
• TABLE 10
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR MANUFACTURING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................48
• TABLE 11
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR MANUFACTURING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................49
• TABLE 12
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR MANUFACTURING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................49
• TABLE 13
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PACKAGING AND LABELING SERVICES, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................50
• TABLE 14
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PACKAGING AND LABELING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)...........................................................51
• TABLE 15
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PACKAGING AND LABELING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)...................................................................51
• TABLE 16
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PACKAGING AND LABELING SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)...........................................................52
• TABLE 17
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR LOGISTICS AND DISTRIBUTION SERVICES, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................53
• TABLE 18
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)....................................................53
• TABLE 19
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)............................................................54
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
17
LIST OF TABLES
• TABLE 20
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2013–2020 (USD MILLION)....................................................54
• TABLE 21
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION).......................................56
• TABLE 22
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION).....................................57
• TABLE 23
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)...............................................................................................................................57
• TABLE 24
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE I TRIALS, BY REGION, 2013–2020 (USD MILLION)...............................................................................................................................58
• TABLE 25
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE I TRIALS, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................58
• TABLE 26
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE II TRIALS, BY REGION, 2013–2020 (USD MILLION)...............................................................................................................................59
• TABLE 27
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE II TRIALS, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................60
• TABLE 28
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE III TRIALS, BY REGION, 2013–2020 (USD MILLION)...............................................................................................................................60
• TABLE 29
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE FOR PHASE III TRIALS, BY COUNTRY, 2013–2020 (USD MILLION).......................................................................................................61
• TABLE 30
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD MILLION).................64
• TABLE 31
CLINICAL TRIAL SUPPLIES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION).....................................64
• TABLE 32
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR ONCOLOGY, BY REGION, 2013–2020 (USD MILLION)..........66
• TABLE 33
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR CNS AND MENTAL DISORDERS, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................67
• TABLE 34
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR CARDIOVASCULAR DISEASES, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................68
• TABLE 35
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................69
• TABLE 36
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR RESPIRATORY DISEASES, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................70
• TABLE 37
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2013–2020 (USD MILLION)..........................................................................................................71
• TABLE 38
CLINICAL TRIAL SUPPLIES MARKET SIZE FOR DERMATOLOGY, BY REGION, 2013–2020 (USD MILLION)...............................................................................................................................72
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
18
LIST OF TABLES
• TABLE 39
CLINICAL TRIAL SUPPLIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2013–2020 (USD MILLION)...............................................................................................................................73
• TABLE 40
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)........................................................................................................78
• TABLE 41
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION)...............................................................................................................................78
• TABLE 42
NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD MILLION)......................................................................................79
• TABLE 43
U.S.: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................80
• TABLE 44
U.S.: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION)..............................81
• TABLE 45
CANADA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)........................................................................................................82
• TABLE 46
CANADA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION).......................82
• TABLE 47
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)........................................................................................................84
• TABLE 48
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION).......................84
• TABLE 49
EUROPE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD MILLION)...............................................................................................................................85
• TABLE 50
U.K.: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................86
• TABLE 51
GERMANY: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)........................................................................................................87
• TABLE 52
FRANCE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...........................................................................................................................................................88
• TABLE 53
SPAIN: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................89
• TABLE 54
ITALY: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................89
• TABLE 55
ROE: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................90
• TABLE 56
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)............................................................................................................93
• TABLE 57
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION)..............93
sales@marketsandmarkets.com
www.marketsandmarkets.com
19
LIST OF TABLES
• TABLE 58
ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD MILLION)...............................................................................................................................94
• TABLE 59
CHINA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................95
• TABLE 60
INDIA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................96
• TABLE 61
JAPAN: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................97
• TABLE 62
ROAPAC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................98
• TABLE 63
ROW: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION)...............................................................................................................................99
• TABLE 64
ROW: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, 2013–2020 (USD MILLION).............................99
• TABLE 65
ROW: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD MILLION).....100
• TABLE 66
EXPANSIONS, 2012–2015...............................................................................................................................104
• TABLE 67
AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND JOINT VENTURE, 2012–2015.............................104
• TABLE 68
ACQUISITIONS, 2012–2015............................................................................................................................105
• TABLE 69
NEW PRODUCT AND SERVICE LAUNCHES, 2012–2015................................................................................106
• TABLE 70
OTHERS, 2012–2015.......................................................................................................................................107
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
20
LIST OF FIGURES
• FIGURE 1
CLINICAL TRIAL SUPPLIES MARKET................................................................................................................15
• FIGURE 2
RESEARCH DESIGN...........................................................................................................................................17
• FIGURE 3
TOP-DOWN APPROACH....................................................................................................................................19
• FIGURE 4
BOTTOM-UP APPROACH..................................................................................................................................19
• FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, & REGION...........................20
• FIGURE 6
DATA TRIANGULATION METHODOLOGY...........................................................................................................21
• FIGURE 7
CLINICAL TRIAL PRODUCTS AND SERVICES MARKET SNAPSHOT, 2015 VS. 2020.......................................25
• FIGURE 8
NORTH AMERICA TO DOMINATE THE LOGISTICS AND DISTRIBUTION MARKET FROM 2015 TO 2020.........26
• FIGURE 9
ONCOLOGY SEGMENT TO COMMAND THE LARGEST MARKET SHARE AND IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD.............................26
• FIGURE 10
PHASE III TO DOMINATE THE CLINICAL TRIAL SUPPLIES MARKET FROM 2015 TO 2020.............................27
• FIGURE 11
CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2015..................................................................................28
• FIGURE 12
ASIA-PACIFIC REGION TO WITNESS HIGHEST GROWTH RATE IN THE CLINICAL TRIAL SUPPLIES MARKET FROM 2015 TO 2020..............................................................................................29
• FIGURE 13
CLINICAL TRIAL SUPPLIES MARKET TO SHOWCASE LUCRATIVE GROWTH OPPORTUNITIES IN THE FORECAST PERIOD....................................................................................................30
• FIGURE 14
LOGISTICS AND DISTRIBUTION SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015.......31
• FIGURE 15
PHASE III SEGMENT TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD..............................32
• FIGURE 16
LOGISTICS AND DISTRIBUTION WILL CONTINUE TO LEAD THE MARKET IN THE FORECAST PERIOD..........33
• FIGURE 17
ASIA-PACIFIC MARKET FOR CLINICAL TRIAL SUPPLIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD.............................................................................................................34
• FIGURE 18
CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES....................................38
• FIGURE 19
LOGISTICS AND DISTRIBUTION SERVICES SEGMENT EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD.....................................................................................................44
• FIGURE 20
NORTH AMERICA EXPECTED TO DOMINATE THE MARKET FOR MANUFACTURING SERVICES IN THE FORECAST PERIOD..............................................................................................................47
• FIGURE 21
PHASE III SEGMENT IS EXPECTED TO DOMINATE THE MARKET IN THE FORECAST PERIOD........................56
• FIGURE 22
ONCOLOGY SEGMENT DOMINATES THE CLINICAL TRIAL SUPPLIES MARKET IN 2015................................63
• FIGURE 23
NORTH AMERICA DOMINATES THE ONCOLOGY MARKET IN 2015.................................................................66
• FIGURE 24
GEOGRAPHIC SNAPSHOT: EMERGING MARKETS HOLD SIGNIFICANT GROWTH OPPORTUNITIES IN THE FORECAST PERIOD....................................................................................................75
• FIGURE 25
NORTH AMERICA: MARKET SNAPSHOT...........................................................................................................77
sales@marketsandmarkets.com
www.marketsandmarkets.com
21
LIST OF FIGURES
• FIGURE 26
PHASE III SEGMENT WILL DRIVE THE GROWTH OF THE CLINICAL TRIAL SUPPLIES MARKET IN THE U.S. IN THE FORECAST PERIOD...........................................................................80
• FIGURE 27
GERMANY IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD...................................................................................................................................83
• FIGURE 28
ASIA-PACIFIC: MARKET SNAPSHOT.................................................................................................................92
• FIGURE 29
EXPANSION WAS THE MAJOR STRATEGY ADOPTED BETWEEN 2012 AND 2015..........................................101
• FIGURE 30
GLOBAL CLINICAL TRIAL SUPPLIES MARKET SHARE, BY KEY PLAYER, 2014..............................................102
• FIGURE 31
BATTLE FOR MARKET SHARE: EXPANSION, THE MOST ACTIVELY ADOPTED STRATEGY BY MARKET PLAYERS...................................................................................................................103
• FIGURE 32
PRODUCT BENCHMARKING FOR MAJOR PLAYERS.......................................................................................108
• FIGURE 33
CATALENT PHARMA SOLUTIONS, INC.: COMPANY SNAPSHOT....................................................................112
• FIGURE 34
PAREXEL INTERNATIONAL: COMPANY SNAPSHOT........................................................................................116
• FIGURE 35
THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT..........................................................................118
• FIGURE 36
SHARP PACKAGING SERVICES: COMPANY SNAPSHOT................................................................................123
sales@marketsandmarkets.com
www.marketsandmarkets.com
22
SAMPLE TABLES
TABLE 1
SIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PHASE, A 2013–2020 (USD MILLION) 2013
2014
2015-e
2020-p
CAGR (2015–2020)
Phase III
xx
xx
xx
xx
xx
Phase II
xx
xx
xx
xx
xx
Phase I
xx
xx
xx
xx
xx
TOTAL
xx
xx
xx
xx
xx
Phase
Source: World Health Organization (WHO), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Generics and Biosimilars Initiative (GaBI), American Association of Pharmaceutical Scientists (AAPS), Generic Pharmaceutical Association (GPhA), Food and Drug Administration (FDA), Committee for Medicinal Products for Human Use (CHMP), ClinicalTrials.gov, the Association of International CROs (AICROS), Association of Clinical Research Organization (ACRO), Association of Clinical Research Professionals (ACRP), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), Indian Society for Clinical Research (ISCR), Expert Interviews, and MarketsandMarkets Analysis
TABLE 2 CLINICAL TRIAL SUPPLIES MARKET SIZE FOR ONCOLOGY, BY REGION, 2013–2020 (USD MILLION) 2013
2014
2015-e
2020-p
CAGR (2015–2020)
North America
xx
xx
xx
xx
xx
Europe
xx
xx
xx
xx
xx
Asia-Pacific
xx
xx
xx
xx
xx
RoW
xx
xx
xx
xx
xx
TOTAL
xx
xx
xx
xx
xx
Region
Source: World Health Organization (WHO), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Generics and Biosimilars Initiative (GaBI), American Association of Pharmaceutical Scientists (AAPS), Generic Pharmaceutical Association (GPhA), Food and Drug Administration (FDA), Committee for Medicinal Products for Human Use (CHMP), ClinicalTrials.gov, the Association of International CROs (AICROS), Association of Clinical Research Organization (ACRO), Association of Clinical Research Professionals (ACRP), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), Indian Society for Clinical Research (ISCR), Expert Interviews, and MarketsandMarkets Analysis
TABLE 3 ASIA-PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY PRODUCTS & SERVICES, 2013–2020 (USD MILLION) 2013
2014
2015-e
2020-p
CAGR (2015–2020)
Logistics and Distribution
xx
xx
xx
xx
xx
Manufacturing
xx
xx
xx
xx
xx
Packaging and Labeling
xx
xx
xx
xx
xx
TOTAL
xx
xx
xx
xx
xx
Products & Services
Source: World Health Organization (WHO), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Generics and Biosimilars Initiative (GaBI), American Association of Pharmaceutical Scientists (AAPS), Generic Pharmaceutical Association (GPhA), Food and Drug Administration (FDA), Committee for Medicinal Products for Human Use (CHMP), ClinicalTrials.gov, the Association of International CROs (AICROS), Association of Clinical Research Organization (ACRO), Association of Clinical Research Professionals (ACRP), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), Indian Society for Clinical Research (ISCR), Expert Interviews, and MarketsandMarkets Analysis
sales@marketsandmarkets.com
www.marketsandmarkets.com
23
RELATED REPORTS
RELATED REPORTS SR. NO.
REPORT TITLE
PUBLISHED DATE
1
Clinical Trials Imaging Market By Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-rays), End User (Pharmaceutical Companies, CROs Medical device Manufacturers), Product (Services, software), and Region - Global Forecast to 2020
2
Clinical Trial Management System (CTMS) Market Site Management, Billing & Patient recruitment, Cloud (SaaS) Global Trends, Opportunities, Challenges and Forecasts till 2016
sales@marketsandmarkets.com
www.marketsandmarkets.com
September 2015
June 2015
24
ABOUT MNM
MarketsandMarkets is a global market research and consulting company. It is World’s No. 2 in terms of premium market research studies published annually. Serving as a business intelligence partner to Fortune 500 companies across the world, it provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers seventeen industry verticals, including advanced materials, aerospace and defense, agriculture, automotive and transportation, biotechnology, building and construction, chemicals, energy and power, food and beverages, industrial automation, medical devices, mining, minerals and metals, packaging, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Copyright © 2015 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
DISCLAIMER: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets’ research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: 1-888-600-6441 sales@marketsandmarkets.com
sales@marketsandmarkets.com
www.marketsandmarkets.com
25